The first Monday of each month, the Knight Initiative for Brain Resilience will host monthly seminars to bring together awardees, affiliated professors and students for a series of 'lab meeting' styled talks. Two speakers will discuss their brain resilience research, experiences in the field, and answer questions about their work.
To support our researchers' participation in this open science ‘lab-meeting style’ exchange of ideas, these seminars are not streamed/recorded and are only open to members of the Stanford community.
Claire Bedbrook, Stanford University
Whole-lifespan behavioral tracking to model aging and predict remaining life
Claire is now a Wu Tsai Neurosciences Institute Interdisciplinary Postdoctoral Scholar in the labs of Professor Karl Deisseroth and Professor Anne Brunet, where she is studying how the brain controls longevity. She hopes to find genes, molecules, and behaviors that extend lifespan and improve health late in life.
Joe Phongpreecha, Stanford University
Cognitive resilience in older age and its medical and genetic associations
I received my Ph.D. in Chemical Engineering from Michigan State University in November of 2018. My thesis relates to machine learning and computational physics for prediction of properties in materials for alternative energy applications. The research was funded in part by my awarded NSF proposal. As a postdoctoral fellow at Stanford, I am fortunate to be a part of both the Aghaeepour lab and the Montine lab. My research focus revolves around different applications of machine learning in neurodegenerative diseases. This ranges from longitudinal neuropsychological studies to single-cell level multiomics and genomics. Currently, I am working on previously unidentified Alzheimer’s and Lewy Body pathologic pattern in human’s brains through development of clustering methods to identify different subpopulations of synapses in single-synapse resolution. In another on-going project, I am employing in-house developed machine learning models to identify blood-based biomarkers for Alzheimer’s disease. The proposal was funded by the Gates Foundation through Alzheimer’s Drug Discovery Foundation. It is my endeavor to push findings from research to advance practices in clinical settings.
